4.72
0.06 (1.29%)
| Penutupan Terdahulu | 4.66 |
| Buka | 4.65 |
| Jumlah Dagangan | 1,303,874 |
| Purata Dagangan (3B) | 3,255,008 |
| Modal Pasaran | 1,292,899,328 |
| Harga / Jualan (P/S) | 212.62 |
| Harga / Buku (P/B) | 5.64 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Nov 2025 |
| Margin Operasi (TTM) | -930.54% |
| EPS Cair (TTM) | -0.340 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -32.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 111.93% |
| Nisbah Semasa (MRQ) | 5.35 |
| Aliran Tunai Operasi (OCF TTM) | -83.45 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -52.28 M |
| Pulangan Atas Aset (ROA TTM) | -35.91% |
| Pulangan Atas Ekuiti (ROE TTM) | -159.34% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Taysha Gene Therapies, Inc. | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | -4.0 |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | -0.90 |
|
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 12.11% |
| % Dimiliki oleh Institusi | 67.23% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Avoro Capital Advisors Llc | 30 Sep 2025 | 21,700,000 |
| Siren, L.L.C. | 30 Sep 2025 | 11,014,737 |
| Octagon Capital Advisors Lp | 30 Sep 2025 | 9,067,500 |
| Vestal Point Capital, Lp | 30 Sep 2025 | 5,500,000 |
| Deerfield Management Company, L.P. | 30 Sep 2025 | 5,386,000 |
| Polar Capital Holdings Plc | 30 Sep 2025 | 5,293,879 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 12.00 (Chardan Capital, 154.24%) | Beli |
| Median | 11.00 (133.05%) | |
| Rendah | 8.00 (Citizens, 69.49%) | Beli |
| Purata | 10.33 (118.86%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 4.73 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Chardan Capital | 06 Jan 2026 | 12.00 (154.24%) | Beli | 5.26 |
| 05 Nov 2025 | 12.00 (154.24%) | Beli | 4.03 | |
| Wells Fargo | 05 Jan 2026 | 11.00 (133.05%) | Beli | 4.89 |
| Citizens | 05 Nov 2025 | 8.00 (69.49%) | Beli | 4.03 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| ALAM KAMRAN | - | 4.69 | -102,817 | -480,558 |
| NAGENDRAN SUKUMAR | - | 4.69 | -116,050 | -542,408 |
| NOLAN SEAN P. | - | 4.69 | -178,101 | -832,429 |
| Jumlah Keseluruhan Kuantiti Bersih | -396,968 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -1,855,396 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 4.69 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| ALAM KAMRAN | Pegawai | 26 Jan 2026 | Jual (-) | 23,849 | 4.72 | 112,567 |
| NOLAN SEAN P. | Pegawai | 26 Jan 2026 | Jual (-) | 41,312 | 4.72 | 194,993 |
| NAGENDRAN SUKUMAR | Pegawai | 26 Jan 2026 | Jual (-) | 26,918 | 4.72 | 127,053 |
| ALAM KAMRAN | Pegawai | 23 Jan 2026 | Jual (-) | 78,968 | 4.66 | 367,991 |
| NOLAN SEAN P. | Pegawai | 23 Jan 2026 | Jual (-) | 136,789 | 4.66 | 637,437 |
| NAGENDRAN SUKUMAR | Pegawai | 23 Jan 2026 | Jual (-) | 89,132 | 4.66 | 415,355 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 06 Jan 2026 | Pengumuman | Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome |
| 05 Dec 2025 | Pengumuman | Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
| 04 Nov 2025 | Pengumuman | Taysha Gene Therapies Reports Third Quarter 2025 Financial Results and Provides Corporate Update |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |